Teva hit on Morgan Stanley downgrade on opioid litigation risk

Teva Pharmaceutical Industries (NYSE:TEVA) slips 5% premarket on modestly higher volume on the heels of a downgrade to Underweight with a $6 (35% downside risk) price target at Morgan Stanley citing its potential exposure from litigation associated with the U.S. opioid epidemic.

https://seekingalpha.com/news/3477610-teva-5-percent-premarket-morgan-stanley-downgrade-opioid-litigation-risk